Dr. Luis Rios Helps to Reduce Use of Opioids

Translate to Spanish or other 102 languages!

Dr. Luis Rios
Dr. Luis Rios

Mega Doctor News

- Advertisement -

Edinburg, TX – Drains, pain, and immobility are what patients fear most after surgery. For years, doctors have prescribed opioids for pain management. Overdoses are now the leading cause of death for Americans under the age of 50, according to the EOCRW (Extension Opioid Crisis Response Workgroup). Opioids for pain relief are generally safe when taken for a short period of time but can lead to dependency due to the euphoric effect they produce.

Dr. Luis Rios a board-certified plastic surgeon told Mega Doctor News that he has a process in place called “Early Recovery After Surgery” that eliminates the use of opioids for patients. Dr. Rios practices at Rios Center for Plastic Surgery.

During a surgical procedure, he offers a one-time injection called Exparel that is infiltrated into the muscle. This modern medicine takes away pain for three days post-procedure; which is the most painful time-frame after surgery.

- Advertisement -

“Through the use of the phenomenal medication, Exparel, I have experienced minimal pain, there’s discomfort, but I’m barely one-week post-op and I’m excited for what’s going to happen next,” said Michelle Garza, a tummy tuck patient.

Exparel’s mission is to control pain management while reducing the use of opioids. It was also pointed out that in addition to Exparel, Dr. Rios also preps patients before surgery by prescribing them non-opioid medication to initiate the pain management process.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Expands Kidney Transplant Program with Transplant Nephrologist, Dr. Victor E. Prado

As part of its ongoing commitment to bringing world-class healthcare to the Rio Grande Valley, DHR Health is pleased to announce the addition of double board-certified transplant nephrologist, Dr. Victor E. Prado. Dr. Prado will provide care to patients at DHR Health’s Transplant Institute,

New Therapy for Head and Neck Squamous Cell Carcinoma Receives Accelerated FDA Approval

The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and immunotherapy.

DHR Health to Host 13th Annual Circle of Care Caregivers Conference

DHR Health Rehabilitation Hospital will host its 13th Annual Circle of Care Caregivers Conference on Saturday, November 7, 2026, at the Edinburg Conference Center at Renaissance, offering educational presentations and resources for individuals caring for family members and loved ones.

HHS Opens $1 Million Funding Opportunity to Strengthen Women’s Preventive Care

The U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), announced a Notice of Funding Opportunity (NOFO) for the Women’s Initiative for Screening and Health (WISH) program.
- Advertisement -